iSpecimen (ISPC) EBIT (2020 - 2026)

iSpecimen's EBIT history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, EBIT fell 54.93% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$9.9 million (up 13.09% YoY), while the FY2025 annual figure was -$9.0 million, up 29.46% from the prior year.
• EBIT for Q1 2026 stood at -$2.5 million, up from -$2.7 million in the prior quarter.
• The five-year high for EBIT was -$1.6 million in Q1 2025, with the low at -$5.8 million in Q4 2024.
• The 5-year median for EBIT is -$2.5 million (2023), against an average of -$2.7 million.
• The sharpest annual moves came in 2022 and 2025: EBIT slumped 150.19% in 2022, then jumped 53.98% in 2025.
• iSpecimen's EBIT stood at -$2.1 million in 2022, then sank by 34.06% to -$2.9 million in 2023, then plunged by 103.43% to -$5.8 million in 2024, then surged by 53.98% to -$2.7 million in 2025, then grew by 5.56% to -$2.5 million in 2026.
• Business Quant data shows ISPC's EBIT at -$2.5 million in Q1 2026, -$2.7 million in Q4 2025, and -$2.8 million in Q3 2025.